EcoDrugPlus

Protein Tyrosine Kinase 2 Beta

Ensembl ID : ENSBBBG00000002002
Gene Symbol: PTK2B
3 Cross references
213 Possible Orthologues:

Protein Tyrosine Phosphatase Non-Receptor Type 11

Ensembl ID : ENSBBBG00000002820
Gene Symbol: PTPN11
3 Cross references
253 Possible Orthologues:

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSBBBG00000003197
Gene Symbol: PTPRB
3 Cross references
268 Possible Orthologues:

Purine Nucleoside Phosphorylase

Ensembl ID : ENSBBBG00000015213
Gene Symbol: LOC104987976
2 Cross references
86 Possible Orthologues:

Purinergic Receptor P2x 3

Ensembl ID : ENSBBBG00000015889
Gene Symbol: P2RX3
3 Cross references
272 Possible Orthologues:

Purinergic Receptor P2x 7

Ensembl ID : ENSBBBG00000016738
Gene Symbol: P2RX7
3 Cross references
195 Possible Orthologues:

Purinergic Receptor P2y1

Ensembl ID : ENSBBBG00000023042
Gene Symbol: P2RY1
1 Cross references
191 Possible Orthologues:

Purinergic Receptor P2y12

Ensembl ID : ENSBBBG00000023493
Gene Symbol: P2RY12
3 Cross references
182 Possible Orthologues:

Purinergic Receptor P2y2

Ensembl ID : ENSBBBG00000002152
Gene Symbol: P2RY2
3 Cross references
200 Possible Orthologues:

Pyrimidinergic Receptor P2y6

Ensembl ID : ENSBBBG00000011676
Gene Symbol: P2RY6
3 Cross references
183 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSBBBG00000021714
Gene Symbol: RAMP1
1 Cross references
252 Possible Orthologues:

Regulatory Associated Protein Of Mtor Complex 1

Ensembl ID : ENSBBBG00000004328
Gene Symbol: RPTOR
3 Cross references
208 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).